Patient-Derived Tumoroid Xenograft Models for Preclinical Validation of Therapeutics in Pleural Mesothelioma (IMIG 2025) - Oct 12, 2025 - Abstract #PM1.29; Pres time: Oct 27, 2025; 12:15 PM - 01:30 PM; Location: Franklin Hall A; "We tested the efficacy of romidepsin (a histone deacetylase inhibitor), sepantronium bromide (SB; a survivin inhibitor), and cisplatin-pemetrexed (CP; standard of care). These tumoroid-based xenograft models effectively recapitulate PM heterogeneity and provide a robust platform for therapeutic testing. Preliminary findings suggest survivin inhibition with sepantronium bromide as a promising strategy, meriting further experiments on different tumoroid cultures. In addition, further drug candidates showing promising yet more tumor-specific susceptibility profiles are currently under investigation, including ixazomib, a proteasome inhibitor, and ganetespib, a heat shock protein 90 (HSP90) inhibitor."
Preclinical • Giant Cell Tumor of Bone • Malignant Pleural Mesothelioma • Mesothelioma • Oncology • Pleural Mesothelioma • Solid Tumor • BIRC5 • CDC37 • HSP90AA1 • VIM
|